Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation; Sanofi/Genzyme Corp; SetPoint Medical Corporation; and Sudo Biosciences, Inc. Aaron Miller, MD, reported affiliations ...

The study, “Multiple sclerosis and gut microbiota ... considering therapies that are highly effective at controlling… Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the ...

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Sanofi plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining ...

Integrating a blood-based biomarker assay into clinical workflows can enhance decision-making in patients with multiple ...

had been diagnosed with multiple sclerosis a year and a half ago. "You only live once, and I want to experience life," he told the outlet. "I’m not going to die with a lot of money. I’m going ...